Annovis Bio receives U.S. patent for new crystalline form of buntanetap
ANVS•Annovis Bio received a U.S. patent on November 3, 2026, covering buntanetap Form B, with protection through June 21, 2044. Form B is used in a fully enrolled pivotal Phase 3 Alzheimer’s trial, with symptomatic results expected in Q1 2027 and disease-modifying results in Q1 2028, and in an open-label Parkinson’s extension study.
1. Patent and trials
Annovis Bio received a U.S. patent on November 3, 2026, covering buntanetap Form B, with protection through June 21, 2044. Form B is used in the fully enrolled pivotal Phase 3 Alzheimer’s trial and an open-label Parkinson’s extension study. Symptomatic results from the Alzheimer’s trial are expected in Q1 2027, followed by disease-modifying results in Q1 2028.
